Can I continue to take Elafibranor after stopping the drug?

Elafibranor (Elafibranor) is an oral selective PPARα/δ agonist. It is mainly used to treat non-alcoholic steatohepatitis (NASH) combined with liver fibrosis and other metabolism-related diseases. During treatment, some patients may need to temporarily discontinue medication due to side effects, improvement of condition, or individual circumstances. So, whether you can continue to take irafibratenol after stopping the drug needs to be analyzed based on the specific situation.

If the drug is discontinued due to short-term non-serious adverse reactions (such as mild gastrointestinal discomfort, fatigue, etc.), as long as the symptoms are relieved and the doctor determines that the patient is still suitable for continued treatment, you can resume taking irafibratenol. This strategy of "shortly stopping medication and then resuming" is common in the treatment of many chronic diseases. The key lies in whether the reason for stopping medication has been resolved and monitoring is done.

If the patient stops taking the drug for a long time (such as more than a few weeks or months), attention should be paid to "re-evaluation" when re-taking irafibratenol, including liver function, metabolic indicators, disease progression, etc. If the condition still meets the indications and there are no serious drug contraindications or organ damage, it can generally be restarted under the guidance of a doctor. Some patients may need to start with a low dose.

However, if the discontinuation is due to serious adverse reactions (such as significant increase in liver enzymes, abnormal creatinine, allergic reactions, etc.), extreme caution is required. Such patients may be at higher risk of taking the drug again, and the risk-benefit ratio should be judged by a specialist and closely monitored, and other alternatives should be selected if necessary.

Finally, patients should never decide to stop or resume medication on their own. Ilafibratenol is a drug in the research and overseas marketing stages (it has not yet been officially launched in China), and its safety and efficacy during use rely on strict medical monitoring. If reuse is needed, professional doctors should be consulted in time to ensure continuity and safety of treatment.

Reference materials:https://www.drugs.com/